摘要
"曲妥珠单抗耐药"概念于2001年基于细胞系和动物模型的实验研究被首次提出,此后众多研究从不同的角度探索曲妥珠单抗耐药的分子机制。目前若干曲妥珠单抗耐药机制的研究已经单独针对原发耐药或继发耐药机制进行,本文对其研究结果进行综述。原发耐药与继发耐药机制的差异提示我们,在曲妥珠单抗治疗中应该根据不同的临床耐药患者亚群给予相应的临床治疗策略。
The conception of trastuzumab resistance is firstly presented in 2001, which is based on the laboratory investigation of cell lines and animal model. After that, numerous studies investigate molecular mechanism of trastuzumab resistance from different angles. The results of several trastuzumab resistance mechanism researches which have directed at primary resistance or acquired resist- ance exclusively are reviewed here. The different mechanisms of primary resistance and acquired resistance of trastuzumab suggest that we should give different clinical therapy strategies to different subgroups of clinical resistance patients.
出处
《临床肿瘤学杂志》
CAS
2012年第6期564-567,共4页
Chinese Clinical Oncology
关键词
曲妥珠单抗
原发耐药
继发耐药
Trastuzumab
Primary resistance
Acquired resistance
